

## Cancelled before Active Statement

Statement on Discontinuation of the Study	
<b>Sponsor</b>	ABCSG (Austrian Breast & Colorectal Cancer Study Group)
<b>EudraCT No.</b>	2009-009874-28
<b>Study Code</b>	ABCSG 34; GA6182E1
<b>Study Title</b>	Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancer
<b>Phase</b>	III
<b>Study Period</b>	NA
<b>No. of Sites</b>	NA
<b>No. of Subjects</b>	0
<b>Publications</b>	NA
<b>Statement on discontinuation of the study:</b> Sponsor rejected study before study start due to results of 2 Ph-III studies with sunitinib in advanced breast cancer which did not meet their primary endpoints. No subjects were recruited, therefore no results/data are available.	